碳酸镧对高钙、高磷维持性血液透析患者钙磷代谢的影响被引量：1

Effect of lanthanum carbonate on serum calcium-phosphate metabolism in dialysis patients with hypercalcinemia and hyperphosphatemia

下载PDF

导出

摘要目的观察碳酸镧治疗血液透析患者高钙、高磷血症的有效性和安全性。方法选择28例存在高钙、高磷血症的维持性血液透析(maintenance hemodialysis,MHD)患者,每日3餐餐中予嚼服碳酸镧咀嚼片,治疗1,2,3个月后对血钙、血磷和PTH水平进行分析评估,并观察不良反应。结果患者口服碳酸镧治疗后血磷、钙磷乘积水平明显下降,而血清钙、甲状旁腺激素等指标在治疗前后并无明显变化(P>0.05)。在服用碳酸镧过程中,无1例患者因严重的不良反应中断治疗。结论碳酸镧能够安全和有效地降低MHD患者的血磷及钙磷乘积水平。 Objective： To assess the efficacy and side effects of lanthanum carbonate in maintenance hemodialysis（ MHD） patients with hypercalcinemia and hyperphosphatemia. Methods： Twenty-eight MHD patients with hypercalcinemia and hyperphosphatemia were prescribed with lanthanum carbonate,three times a day in mealtime. Before and after using lanthanum carbonate therapy for 1,2 and 3 months,the serum calcium,phosphorus and intact parathyroid hormone were measured,and the side effects were also observed. Results： After treatment,serum phosphorus and calcium-phosphorus products decreased significantly（ P〈0. 05）. The serum calcium,and serum parathyroid hormone showed no obvious variation（ P〈0. 05）. The side effects of lanthanum carbonate were weak. No patient dropped therapy and no serious adverse events were observed. Conclusion： The management of hyperphosphatemia with lanthanum carbonate in MHD patients is safe and effective.

作者王维平熊长青朱鹏

机构地区扬州市江都人民医院肾内科

出处《泰山医学院学报》 CAS 2015年第7期762-764,共3页 Journal of Taishan Medical College

关键词高磷血症维持性血液透析碳酸镧 hyperphosphatemia maintenance hemodialysis lanthanum carbonate

分类号 R692.5 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献13

1Tentori F, Biayney M J, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and lcrrH:the Dialysis Outcomes and Practice Patterns Study (DOPPS) [J]. Am J Kidney Dis,2008,52:519 -530.
2Petrovie D, Obrenovie R, Trbojeyic-Stankovi J, et al. Serum cysta- tin C Leveis in normal pregnancy [ J ]. Clin Nephrol, 201 I, 76 ( 3 ) : 174 - 179.
3Adeney KL, Siscoviek DS, K JH, et al. Association of serum phos- phate with vascular and valvular calcification in moderate CKD[J]. J Am Soc Nephrol,2009,20(2) :381 -387.
4方艺,丁小强,邹建洲,方燕,钱家麒,戎殳,梅长林,邱强,陈香美,郑智华,余学清.盐酸司维拉姆治疗维持性血液透析患者高磷血症的短期疗效[J].中华肾脏病杂志,2012,28(3):183-188. 被引量：24
5孙岩,兰超,张菁菁,陈李萨,热娜,赵新,李素华,王梅红,刘珍,桑晓红,刘健.醋酸钙片治疗腹膜透析患者高磷血症的疗效观察[J].中国中西医结合肾病杂志,2013,14(9):784-786. 被引量：18
6Asd G,Ozkahya M,Duman S,et al. The link between eardioaselllar and bone disease in hemodialysis patients[ J ]. Nephrol Dial Trans- plant,2007,22(6 ) :214 - 217.
7M hlenkamp S, Moebus S, Sehmenund A,et al. Assessment of the natural history of coronary artery calcification and identification of its determinants. Rationale of the 2nd part of the Heinz Nixdoff Re- call Study[ J]. Harz,2007,32(2) : 108 - 120.
8Raggi P, Vukicevic S, Moys6s RM,et al. Ten-year experience with sevelamer and calcium salts as phosphate binders [ J ]. CAin J Am Soc Nephrol,2010,5 Suppll :S31-40.
9Patel TV, Singh AK. Kidney disease outcomes quality initiative guidelines for bone and mineral metabolism: emerging questions [J]. Semin Nephrol, 2009, 29(2):105 -112.
10Yamada K, Fujimoto S, Nishiura R, et al. Risk factors of the pro- gression of abdominal aortic calcification in patients on chronic haemodialysis[ J]. Nephrol Dial Transplant,2007,22 (7) :2032 - 2037.

二级参考文献46

1Raggi P, Vukicevic S, Moys6s RM, et al. Ten-year experience with sevelamer and calcium salts as phosphate binders. Clin J Am Soc Nephrol, 2010, 5 Suppl 1: S31- S40.
2Sturtevant JM, Hawley CM, Reiger K, et al. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders. Nephrology (Carlton), 2004, 9: 406-413.
3Nikolov IG, Joki N, Maizel J, et al. Pleiotropic effects of the non-calcium phosphate binder sevelamer. Kidney Int Suppl, 2006, 105: S16-S23.
4Noordzij M, Korevaar JC, Boeschoten EW, et al. Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis, 2005, 46: 925-932.
5Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers scram phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int, 1999, 55: 299-307.
6Goldberg DI, Dillon MA, Slatopolsky EA, et al. Effect of RenaGel, a non-absorbed, calcium-and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant, 1998, 13: 2303-2310.
7Cassidy M J, Owen JP, Ellis HA, et al. Renal osteodystrophy and metastatic calcification in long-term continuous ambulatory peritoneal dialysis. Q J Med, 1985, 54: 29-48.
8Slatopolsky EA, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int, 1999, 55: 299-307.
9Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis, 1999, 33: 694- 701.
10Koiwa F, Onoda N, Kato H, et al. Prospective randomized muhicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. Ther Apher Dial, 2005, 9: 340-346.